Storia in 3 fonti

FDA clears Bayer’s Hyrnuo in first-line lung cancer, amping up Hernexeos rivalry

In an accelerated decisio | Bayer has won first-line approval for its tyrosine kinase inhibitor, Hyrnuo, in patients with HER2-mutant non-small cell lung cancer. The green light comes around half a year after a similar nod for rival TKI med Hernexeos from Boehringer Ingelheim.

Raccontata da

healio.com

fiercepharma.com

morningstar.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

fiercepharma.comStai leggendo1 g fa

FDA clears Bayer’s Hyrnuo in first-line lung cancer, amping up Hernexeos rivalry

originale

healio.com2 g fa

FDA OKs accelerated approval to frontline Hyrnuo for non-small cell lung cancer

The FDA has granted accelerated approval to sevabertinib as first-line treatment for adults with locally advanced or metastatic non-squamous non-small cell lung cancer.The approval of sevabertinib (Hyrnuo, Bayer…

Leggi questa versione →

FDA clears Bayer’s Hyrnuo in first-line lung cancer, amping up Hernexeos rivalry

Confronto fonti

FDA clears Bayer’s Hyrnuo in first-line lung cancer, amping up Hernexeos rivalry

FDA OKs accelerated approval to frontline Hyrnuo for non-small cell lung cancer

Timeline cronologica

FDA OKs accelerated approval to frontline Hyrnuo for non-small cell lung cancer

FDA clears Bayer’s Hyrnuo in first-line lung cancer, amping up Hernexeos rivalry

U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for…

U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated…